



## An integrated medical treatment for type-2 diabetes

This is the peer reviewed version of the following article:

*Original:*

Bocci, V., Zanardi, I., Huijberts, M.S.P., Travagli, V. (2014). An integrated medical treatment for type-2 diabetes. *DIABETES & METABOLIC SYNDROME*, 8(1), 57-61 [10.1016/j.dsx.2013.10.004].

*Availability:*

This version is available <http://hdl.handle.net/11365/45324> since 2016-11-19T09:59:22Z

*Published:*

DOI:10.1016/j.dsx.2013.10.004

*Terms of use:*


Open Access

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license.

For all terms of use and more information see the publisher's website.

(Article begins on next page)

**AUTHOR QUERY FORM**

 <b>ELSEVIER</b>	<b>Journal:</b> DSX	<b>Please e-mail or fax your responses and any corrections to:</b>
	<b>Article Number:</b> 356	<b>E-mail:</b> <a href="mailto:corrections.esch@elsevier.thomsondigital.com">corrections.esch@elsevier.thomsondigital.com</a> <b>Fax:</b> +353 6170 9272

Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. Note: if you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of your paper please return your corrections within 48 hours.

For correction or revision of any artwork, please consult <http://www.elsevier.com/artworkinstructions>.

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof. Click on the 'Q' link to go to the location in the proof.

<b>Location in article</b>	<b>Query / Remark: <a href="#">click on the Q link to go</a> Please insert your reply or correction at the corresponding line in the proof</b>
<a href="#">Q1</a> <a href="#">Q2</a>	<p>Please confirm that given names and surnames have been identified correctly. Please provide an abstract.</p> <div style="border: 1px solid black; padding: 10px; margin-top: 20px;"> <p>Please check this box or indicate your approval if you have no corrections to make to the PDF file <input type="checkbox"/></p> </div>

Thank you for your assistance.



Contents lists available at ScienceDirect

# Diabetes & Metabolic Syndrome: Clinical Research & Reviews

journal homepage: [www.elsevier.com/locate/dsx](http://www.elsevier.com/locate/dsx)



## Perspective

### An integrated medical treatment for type-2 diabetes

Q1 **Velio Bocci<sup>a,\*</sup>, Jacopo Zanardi<sup>b</sup>, Maya S.P. Huijberts<sup>c</sup>, Valter Travaglini<sup>b,\*\*</sup>**

<sup>a</sup> Department of Physiology, University of Siena, Siena, Italy

<sup>b</sup> Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy

<sup>c</sup> Department of Internal Medicine, Division of Endocrinology, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands

#### ARTICLE INFO

##### Keywords:

Diabetes  
Oxidative stress  
Oxygen-ozonotherapy  
Antioxidants  
Nrf2 activation

#### Contents

1. Introduction	000
1.1. Anatomico-biochemical alterations of type 2 diabetes	000
1.2. Progression of type 2 diabetes is dominated by a chronic oxidative stress	000
1.3. The integration of orthodox drugs with ozone therapy	000
1.3.1. Mechanisms of action of ozone in blood	000
2. Concluding remarks	000
References	000

#### 1. Introduction

Q2 In 2000, with some approximation, it was estimated that there were 170 million people suffering from diabetes. This number has grown to 346 million people in 2012 and it has been supposed that in 2030 there will be 439 million diabetic patients [1]. If indeed about 6% of the world population will suffer from diabetes, by adding the huge number of patients affected by possibly concomitant chronic cardiovascular diseases, it will represent an unsustainable socioeconomic burden. Ironically, in spite of the prolongation of the life-span, an erroneous life style leads to such a high number of patients who will further unbalance the cost of medical expenses.

Diabetes mellitus can mainly manifest into three categories: 23  
Type 1-, gestational-, and type 2- diabetes. Type 1 diabetes mostly 24  
happens in children (about 10%) and for practical reasons it will be 25  
not discussed here. Gestational diabetes needs careful medical 26  
supervision throughout the pregnancy, but normally disappears 27  
after delivery. On the contrary, type 2 diabetes includes almost 90% 28  
of patients and tends to be progressive, unless an effective 29  
treatment is adopted. The progression of type 2 diabetes induces a 30  
multiform pathology complicated by a chronic oxidative stress. 31  
Careful dieting associated with moderate physical exercise and 32  
above all antidiabetic drugs have an important role in slowing 33  
down the progression of the disease. Medical treatment, though 34  
efficacious, does not always normalize the deranged metabolism. 35  
Moreover, the biochemical dysfunction is accompanied by a 36  
progressively worsening of a chronic oxidative stress, with 37  
complex anatomico-pathological lesions at the level of many organs. 38  
The concomitant use of oral antioxidants certainly is not harmful, 39  
but it is practically ineffective in normalizing the redox system. On 40  
the other hand, in the last decade it has been demonstrated that the 41  
Nrf2/Keap1 signalling pathway is the master system for cell 42  
defence against oxidative stress and, if properly activated, can 43  
resurrect the cellular redox balance at physiological levels [2–4]. 44

\* Corresponding author at: Emeritus Professor of Physiology at the Department of Physiology, University of Siena, Viale A. Moro 2, 53100, Italy. Tel.: +39 577 234226; fax: +39 577 234219.

\*\* Corresponding author at: Chief of the Post-Graduate School of Hospital Pharmacy, University of Siena, Viale A. Moro, 2, 53100, Italy. Tel.: +39 577 234226; fax: +39 577 234219.

E-mail addresses: [velio.bocci@unisi.it](mailto:velio.bocci@unisi.it) (V. Bocci), [valter.travaglini@unisi.it](mailto:valter.travaglini@unisi.it) (V. Travaglini).

During the last few years we have clarified that precisely treating blood with therapeutic ozone concentrations induces the formation of two messengers such as hydrogen peroxide and alkenals [5]. The latter, especially 4-hydroxynonenal (4-HNE), is an electrophile able to inhibit the suppressive action of Keap1 allowing the translocation of Nrf2 into the nucleus and the binding to the Antioxidant Response Elements (ARE) [6,7]. Such a mechanism is optimally activated by ozone therapy, a complementary approach of which the biological and molecular aspects have been thoroughly evaluated during the last two decades [5]. In fact, both preclinical and clinical studies in diabetes as well as in chronic oxidative stress have shown its validity in reactivating the innate antioxidant system [8]. Consequently, the integration of orthodox medical treatment with this approach can normalize the redox system and it is likely to significantly reduce the diabetic dysfunctions.

### 1.1. *Anatomo-biochemical alterations of type 2 diabetes*

The first problem is usually referred to the hyperglycemia due either to the insulin receptor resistance or to a decreased insulin secretion [9]. As obesity frequently accompanies type 2 diabetes, the release of detrimental adipokines from adipose tissues further complicates the disease [10]. The following biochemical mechanisms are greatly responsible for the glucose-mediated vascular damage:

- (a) Increased formation of advanced glycation end products (AGEs). Their development has been recognized as an important pathophysiological mechanism in the development of diabetic complications [11,12]. The Maillard reaction is a non-enzymatic glycosylation occurring when an  $\alpha$ -amino group of the  $\beta$ -chain of haemoglobin reacts with a reducing sugar such as glucose. The reaction yields Schiff-base intermediates, which undergo the Amadori rearrangements to stable ketoamine derivatives. These compounds degrade into a variety of  $\alpha$ -dicarbonyl compounds able to react with proteins forming irreversible AGEs which, taken up by cell receptors (RAGEs), stimulate the synthesis of proinflammatory cytokines such as IL-1 and TNF- $\alpha$  and of matrix proteins able to induce an irreversible damage. AGEs are detrimental for endothelial cells present in the corneal stroma and in the lens, accelerating cataract formation. Moreover, they particularly damage the vascular and neuronal system;
- (b) activation of protein kinase C isoforms enhances the amount of diacylglycerol in vascular cells;
- (c) the abnormally high glycemia is shunted into the hexosamine pathway leading to increased production of TGF- $\beta$ 1 and plasminogen activator inhibitor-1;
- (d) an increased polyol pathway flux. Activation of aldose reductase leads to increased conversion of glucose to sorbitol with concomitant decrease in NADPH useful for regenerating oxidized GSH. The reduced GSH/GSSG ratio decreases the antioxidant defence. Moreover, a decrease of NO synthesis leads to enhanced platelet aggregation and vasoconstriction [13];
- (e) type 2 diabetic patients often have infections due to immunological mediated acute phase reactions: experimental data have shown elevated levels of serum amyloid A, C-reactive protein and development of inflammatory responses [14,15]. Long-term type 2 diabetes frequently shows a decreased chemotaxis of neutrophils [16], an impaired monocyte adhesion to vascular endothelium [17] and a reduced phagocytic activity [18]. The increased levels of circulating and pathogenic immune complexes (IC) have been detected [19] and their deposition in the endothelium causes an inflammatory

response by the activation of the complement cascade. In comparison to healthy controls, C1, C2, C3 and C4 proteins were significantly higher in type 2 diabetic patients [20] inducing the formation of micro- and macrovascular diseases.

The initial problem of type 2 diabetes is the hyperglycemia frequently due to insulin resistance, possibly combined to reduced insulin secretion. In obesity, there is a different production and release of adipokines in comparison to the release of adiponectin and leptin occurring in normal subjects. The release of resistin and of pro-inflammatory cytokines (IL-1; IL-6 and TNF $\alpha$ ) from adipocytes, fibroblasts, macrophages and monocytes present in adipose tissue appears involved in mediating insulin resistance in peripheral tissues [10]. Needless to say that a careful control of glycemia and glycosylated haemoglobin with an appropriate and a fairly restricted diet associated with daily exercise is important. Otherwise, a diffused macrovascular disease can lead to the following complications:

- (a) atherosclerosis can become evident with hypertension, myocardial infarction, stroke and limb vascular obstruction complicated with necrotic ulcers. Diabetic foot disease is frequently accompanied by polyneuropathy and infected foot ulcers [21];
- (b) neuropathy may involve both the somatic and autonomic nervous system with neuromuscular dysfunction and wasting;
- (c) diabetic nephropathy occurs in about 30% of patients and it may lead to end stage renal disease;
- (d) diabetic retinopathy may cause blindness in the majority of patients.

### 1.2. *Progression of type 2 diabetes is dominated by a chronic oxidative stress*

Baynes [22] was one of the first to emphasize the role of a diffused oxidative stress. West [23] suggested a scheme indicating the interaction between hyperglycemia and the increased production of reactive oxygen species (ROS) such as  $O_2^{\cdot-}$ ,  $H_2O_2$ ,  $\cdot OH$ ,  $ONOO^-$ . An excessive consumption with a decreased synthesis of GSH leads to a lower GSH/GSSG ratio, which is a significant marker of oxidative stress. Another negative aspect is due to the AGE compounds binding to the endothelium and to the erythrocyte membrane favouring a worsening of the oxidative stress because the cellular innate molecular mechanism of restoring antioxidant enzymes (SOD, GSH-reductase and transferase, catalase, etc.), phase-2 enzymes and HO-1 is somewhat inhibited and incapable of neutralizing the excess of oxidants.

Orthodox medicine disposes of excellent drugs as antidiabetics, statin, antihypertensive and anticoagulants but their administration, although slowing down diabetes progression, cannot re-establish a normal redox system because some of these drugs are unable to reactivate the cellular antioxidant system. However, after two decades of intensive work, it is now possible to use a complementary system able to normalize the redox system [5,7]. The integration of this approach with orthodox medicine may indeed interrupt this vicious circle and can be very helpful to the patient.


### 1.3. *The integration of orthodox drugs with ozone therapy*

Nowadays, ozone therapy is used every day in most public hospitals in India, China, Russia and Cuba and in private clinics by many physicians, particularly in Germany. However, orthodox medicine disregards ozone therapy either owing to the lack of knowledge or simply by preconception based on the well-known

ozone toxicity. This view is completely outdated because firstly ozone, like other gases such as NO, CO, H<sub>2</sub>S and H<sub>2</sub> are only used in therapeutic doses [24] and it is known that the toxicity of any chemical compound depends upon the dosage [25]. The second important remark is that ozone toxicity for the pulmonary system [26] depends upon critical parameters such as the ample alveolar surface, the minimal volume of the alveolar surface lining (about 30 mL), its minimal antioxidant capacity, many fold less than plasma, and the cumulative effect of inhaling ozone per months. Thus, the dogma that ozone is always toxic is untenable [27] and indeed the performance of ozone therapy during the last three decades has shown to be effective and without side effects. This is due to the potent antioxidant capacity of human plasma [28] and the use of ozone concentrations within the therapeutic range (10–80 µg/mL of gas per mL of blood, or 0.21–1.68 mM per mL of blood). Moreover, thanks to the modern ozone generators, the ozone concentration is precisely measured in real time within the Hartley band at 253.4 nm. The volume of the gas mixture composed of medical oxygen (≥95%)-ozone (≤5%) is controlled by a calibrated ozone-resistant syringe at normal atmospheric pressure.

### 1.3.1. Mechanisms of action of ozone in blood

These aspects have been already extensively discussed elsewhere [5,8,29,30] and they will be summarized. Two phases need to be described: the first phase happens *ex vivo* in a 250–500 mL sterile glass bottle where a volume of blood (100–150 mL) comes in close contact with an equal volume of the oxygen–ozone mixture. As blood has a potent antioxidant capacity, equivalent to 1.28–1.83 mmol/l plasma [28], some of the ozone dose dissolved in the water of plasma is immediately quenched by uric acid, ascorbic acid, GSH, cysteine and albumin, while the remaining ozone reacts with polyunsaturated fatty acids (PUFA), giving a mixture of heterogenous lipid oxidation products including alkenals, schematically as follows:



Owing to the high ozone solubility and reactivity, this reaction is completed in 30–50 s and ozone is totally exhausted while oxygen, dissolved in the plasma water, fully saturated haemoglobin. Blood oxygenation is however irrelevant because the ozonated blood is slowly infused into the donor patient within a few minutes and mixes with venous blood. At this stage, the two important messengers generated by the ozone reactions are hydrogen peroxide and aldehydes as the end products of the PUFA peroxidation. While half of the uric acid is oxidized to allantoin and excreted, dehydroascorbate and a trace of GSH disulfide are reduced back to their normal value within a few minutes by a well-coordinated sequence of electron donations by thioredoxin, vitamin E and NADPH [31].

The unionized hydrogen peroxide enters into all blood cells (at most about 4 µM) because the chemical gradient between plasma and cells is only about 10% of its extracellular concentration [32,33]. The sudden and very brief inflow of hydrogen peroxide inside blood cells is the indispensable stimulus to activate a number of biochemical reactions as follows:

(i) in the erythrocytes it causes the activation of glycolysis with a significant increase of ATP and 2,3-diphosphoglycerate. Consequently the oxyhemoglobin sigmoid curve shifts to the right and increases the release of oxygen especially at the level of ischaemic tissues. Due to the great number of erythrocytes, hydrogen peroxide is promptly reduced to water by GSH. The altered GSH/GSSG ratio is quickly corrected by either extruding some glutathione disulphide, or by reducing

it via GSH reductase at the expense of either ascorbic acid or thioredoxin. Moreover, the activation of the G6PDH provides reducing power and activate glycolysis [7,30];

(ii) In the leukocytes: neutrophil phagocytic activity is enhanced. Hydrogen peroxide entering into lymphocytes and monocytes activate a tyrosin-kinase with consequent phosphorylation of IκB, one of the trimeric components at rest of the transcription factor NF-κB. The phosphorylated IκB becomes free and is lysed in the proteasome. The remaining heterodimer p50–p65 translates into the nucleus and activates a variety of genes leading to a small release of γ-interferon and IL-8 [34–36]. The slight immune enhancing effect remains limited to the ozonated leukocytes.

(iii) as platelets are sensitive to even a slight oxidation, they tend to release their growth factors, which is relevant in enhancing the healing of ulcers in peripheral obstructive arterial disease [37].

The chemical reactions between blood and ozone are happening in a few minutes and then the ozonated blood is quickly infused into the donor patient. During this important second phase, some of the lipoperoxides formed during the ozonation phase are either reduced to hydroperoxide, further broken down by GSH transferase, or leading to the formation of 4-HNE. This alkenal is an electrophilic, amphipathic molecule which forms an adduct with either GSH, or cysteine, or preferentially with Cys34 present in the domain-1 of albumin. Owing to the amount of both intra and extravascular albumin (about 280 g), alkenals undergo a great dilution in body fluids. Alkenals are also broken down by GSH-S-transferases, aldehyde dehydrogenase and other enzymes [38] and some are also eliminated via renal and bile excretion [39]. The remaining submicromolar concentration of alkenals bound to albumin become the most critical ozone messengers because they are being released at many sites and inform a variety of cells of a transitory, acute oxidative stress. Albumin can transport alkenal adducts in all body tissues, from liver to endocrine glands and the hypothalamus. Once they are internalized, this electrophilic molecule reacts with –SH and NH<sub>2</sub> groups of the inert complex Nrf2-Keap1 in the cytosol where Keap1 is bound to the actin cytoskeleton. Keap1 (Kelch-like ECH-associated protein 1) is a protein molecule with many –SH groups but Cys272 and Cys288 are important for the repression of Nrf2 activity [4]. Normally the complex Nrf2-Keap1 has a half life of about 20 min because Keap1 is readily ubiquitinated and digested in the proteasome. However the alkenal interaction with Cys 151 of Keap-1 allows the release of Nrf2, which escapes proteasomal degradation and translocates into the nucleus, heterodimerizes with a small Maf protein and binds to the Antioxidant Response Element (ARE or EHRE) on DNA [2–4].

On this basis, it is clear that the Nrf2-Keap1 system is now correctly recognized as the master cellular defence system against oxidative and xenobiotic stresses. Moreover it is reassuring that this defence system can be activated in hepatic, renal, pulmonary, cardiac, ovarian and neuronal cells.

The infusion of the ozonated blood into the donor patient expresses also other beneficial effects: one is the stimulation of endothelial NO synthase. Consequently the release of NO, S-nitrosothiols and a trace of CO released with bilirubin, via the upregulation of HO-1 activity, improves vasodilation and oxygenation of ischaemic tissues. Another advantage is the enhanced release of prostacyclin (PGI<sub>2</sub>) due to a stimulation of cyclo-oxygenase 1 [40]. In conclusion the mild oxidative stress induced by the infusion of ozonated blood can activate several biological responses of which the most important are characterized by the synthesis of several protective pathways as follows:

- 312 (a) the up-regulation of the synthesis of antioxidant enzymes such  
314 as catalase, SOD, GSH-peroxidases, GSH-reductase, NADPH-  
315 quinone oxidoreductase able to neutralize the excess of ROS;  
316 (b) the enhancement of synthesis and levels of phase-II enzymes;  
318 (c) upregulation of HO-1 so that a trace of CO in synergy with NO  
320 allows vasodilation of **ischaemic tissues**;  
322 (d) an increased synthesis of GSH as well as an increased reduction  
323 of GSSG via ascorbic acid, and thioredoxin reductase;  
324 (e) an inhibition of the synthesis of pro-inflammatory cytokines  
326 via the induction of leukotriene B4 reductase;  
328 (f) a reduction of Fe<sup>2+</sup> overload via an increased synthesis of ferritin;  
329 (g) a generation of a feeling of well-being throughout the ozone  
331 therapy sessions.

332 Regarding this last point it is very likely that alkenals bound to  
333 GSH stimulate the neurons of the supra-aortic nucleus in the  
334 hypothalamus with a release of CRF-ACTH and, finally, cortisol [7].  
335 This may explain the feeling of wellness reported by the majority of  
336 patients during ozone therapy.

337 The very low level of therapeutic ozone is consistent with the  
338 pharmacological concept of hormesis which clarifies how a  
339 therapeutic effect results from the response of an organism to a  
340 low-intensity biological stressor [41,42]. In line with this concept,  
341 the initial ozone dosage must be at the lowest levels of **10-15 µg/**  
342 **mL per mL of blood**. Indeed the axiom: "start low, go slow" has  
343 been adopted and only during the following sessions the ozone  
344 dosages can be slowly upgraded up to a maximum of **35-40 µg/**  
345 **mL per mL of blood**. Previous clinical experience has indicated that  
346 the very moderate oxidative stress induced by ozone therapy must  
347 be repeated for a prolonged time, especially for diabetes, before  
348 noticing an improvement and possibly a normalization of the  
349 redox state [5]. The protocol foresees the application of ozonated  
350 autohemotherapy either three times, or twice weekly, depending  
351 upon the stage of the disease for at least five months. Almost  
352 needless to say is that the sooner the ozonotherapy begin, the  
353 better. Then, on the basis of the clinical and hematochemical  
354 results, the frequency of the treatment may be reduced to once  
355 weekly for the following six months. In order to maintain an  
356 efficient antioxidant level, autohemotherapy at a slower pace can  
357 be continued for life. There other several modalities of ozone  
358 administration [6,43] but the autohemotherapy approach is the  
359 most valid and the compliance of the patient is excellent. It is  
360 worth mentioning that infections and ulcers of the diabetic foot  
361 can be effectively treated [44,45] and topical application of  
362 ozonated oils [46-48]. It is also necessary to mention that  
363 experimental studies performed in laboratory animals have  
364 already shown that a minimal oxidative preconditioning with  
365 low ozone dosages yields a significant induction of antioxidant  
366 enzymes [49-51]. There are also a number of anecdotic studies  
367 performed by physicians, who privately have evaluated the value  
368 of ozonated autohemotherapy in diabetic patients. The results  
369 have shown that there is a marked reduction of insulin-resistance  
370 and often the need to suspend insulin therapy [8]. In spite of the  
371 dictum "*in patients veritas*", anecdotic results have a minimal value  
372 and it appears therefore necessary and urgent to perform  
373 randomized and well-controlled clinical trials. The results of these  
374 studies would be very informative especially because in leptin  
375 deficient (ob/ob)-Keap1-knockdown mice a constant activation of  
376 Nrf2 activity is generated and appears counterproductive [52,53].  
377 Needless to say that ozone therapy can be easily modulated on the  
378 basis of the clinical and hematologic parameters.

## 379 2. Concluding remarks

380 In this paper we have briefly reviewed the progressive stages of  
381 type 2 diabetes. Hyperglycemia, AGE compounds and other

metabolic disturbances are able to induce a micro- and macro-  
382 vascular dysfunction leading to a great number of complications.  
383 One considerable problem is the progressive development of a  
384 chronic oxidative stress and antidiabetic drugs, though effective,  
385 are unable to readjust the redox system. It appears useful to  
386 integrate the orthodox therapy with an appropriate complemen-  
387 tary approach of which today we exactly know the biochemical  
388 pathway, the molecular mechanisms of action, and the lack of  
389 toxicity. Administration of oral antioxidants is certainly useful, but  
390 it is unable to correct the chronic oxidative stress because it does  
391 neither allow the neutralization of intracellular oxidative species,  
392 nor it is able to actively stimulate the innate antioxidant system. To  
393 the best of our knowledge, ozone therapy is the unique procedure  
394 able to reactivate the depressed antioxidant system and to improve  
395 hemorheological parameters. Therefore by considering the diabet-  
396 ic epidemiology and the urgency to fully correct the complex  
397 dysfunction, it appears necessary to integrate orthodox medica-  
398 tions with ozone therapy.  
399

## 400 Author contributions

401 VB conceived the paper, collated and analyzed the data,  
402 wrote manuscript, gathered references. IZ helped to critical  
403 revision of the drafts, gathered references. MH assisted with the  
404 critical editing of the paper. VT planned/drafted the paper,  
405 refined the search for information, analyzed the data, wrote  
406 manuscript, gathered references. All the Authors approved the  
407 final manuscript.

## 408 Conflict of interest

409 The authors have not received any fund for this work and  
410 declare that they have no conflict of interest.

## 411 References

- 412 [1] Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes  
413 for 2010 and 2030. *Diab Res Clin Pract* 2010;87:4-14.
- 414 [2] Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important  
415 stress response mechanism. *Trends Mol Med* 2004;10:549-57.
- 416 [3] Zhang DD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. *Drug*  
417 *Metab Rev* 2006;38:769-89.
- 418 [4] Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1-  
419 Nrf2 pathway in stress response and cancer evolution. *Genes Cells*  
420 2011;16:123-40.
- 421 [5] Bocci V, Borrelli E, Travagli V, Zanardi I. The ozone paradox: ozone is a strong  
422 oxidant as well as a medical drug. *Med Res Rev* 2009;29:646-82.
- 423 [6] Sagai M, Bocci V. Mechanisms of action involved in ozone therapy: is healing  
424 induced via a mild oxidative stress? *Med Gas Res* 2011;1:29. <http://dx.doi.org/10.1186/2045-9912-1-29>.
- 425 [7] Bocci V. How a calculated oxidative stress can yield multiple therapeutic  
426 effects. *Free Radic Res* 2012;46:1068-75.
- 427 [8] Bocci V, Zanardi I, Huijberts MS, Travagli V. Diabetes and chronic oxidative  
428 stress. A perspective based on the possible usefulness of ozone therapy. *Diab*  
429 *Metab Syndr* 2011;5:45-9. <http://dx.doi.org/10.1016/j.dsx.2010.05.014>.
- 430 [9] Brownlee M. A radical explanation for glucose-induced beta cell dysfunction.  
431 *J Clin Invest* 2003;112:1788-90.
- 432 [10] Haas B, Schlinkert P, Mayer P, Eckstein N. Targeting adipose tissue. *Diabetol*  
433 *Metab Syndr* 2012;4:43. <http://dx.doi.org/10.1186/1758-5996-4-43>.
- 434 [11] Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggese A, Bakker K, et al. High  
435 prevalence of ischaemia, infection and serious comorbidity in patients with  
436 diabetic foot disease in Europe. Baseline results from the Eurodiale study.  
437 *Diabetologia* 2007;50:18-25.
- 438 [12] Huijberts MS, Schaper NC, Schalkwijk CG. Advanced glycation end products  
439 and diabetic foot disease. *Diab Metab Res Rev* 2008;24(Suppl. 1):S19-24.
- 440 [13] Cameron NE, Cotter MA. The relationship of vascular changes to metabolic  
441 factors in diabetes mellitus and their role in the development of peripheral  
442 nerve complications. *Diab Metab Rev* 1994;10:189-224.
- 443 [14] Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? **An**  
444 **update**. *Diab Med* 2004;21:203-7.
- 445 [15] Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. *Nat Rev*  
446 *Immunol* 2011;11:98-107.
- 447 [16] Delamair M, Maugeudre D, Moreno M, Le Goff MC, Allannic H, Genetet B.  
448 Impaired leucocyte functions in diabetic patients. *Diab Med* 1997;14:  
449 29-34.  
450

- [17] Jialal I, Devaraj S, Venugopal SK. Oxidative stress, inflammation, and diabetic vasculopathies: the role of alpha tocopherol therapy. *Free Radic Res* 2002;36:1331–6.
- [18] Lecube A, Pachón G, Petriz J, Hernández C, Simó R. Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement. *PLoS ONE* 2011;6:e23366. <http://dx.doi.org/10.1371/journal.pone.0023366>.
- [19] Burut DF, Karim Y, Ferns GA. The role of immune complexes in atherogenesis. *Angiology* 2010;61:679–89.
- [20] Engström G, Hedblad B, Eriksson KF, Janzon L, Lindgärde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. *Diabetes* 2005;54:570–5.
- [21] Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. *Diab Care* 2001;24:1433–7.
- [22] Baynes JW. Role of oxidative stress in development of complications in diabetes. *Diabetes* 1991;40:405–12.
- [23] West IC. Radicals and oxidative stress in diabetes. *Diab Med* 2000;17:171–80.
- [24] Nakao A, Sugimoto R, Billiar TR, McCurry KR. Therapeutic antioxidant medical gas. *J Clin Biochem Nutr* 2009;44:1–13.
- [25] Timbrell J. In: Timbrell J, editor. *The poison paradox chemicals as friends and foes*. New York, NY: Oxford University Press; 2005.
- [26] Jerrett M, Burnett RT, Pope 3rd CA, Ito K, Thurston G, Krewski D, et al. Long-term ozone exposure mortality. *N Engl J Med* 2009;360:1085–95.
- [27] Bocci V. Is it true that ozone is always toxic? *The end of a dogma. Toxicol Appl Pharmacol* 2006;216:493–504.
- [28] Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. *Methods Enzymol* 1994;234:279–93.
- [29] Bocci V. The case for oxygen-ozone therapy. *Br J Biomed Sci* 2007;64:44–9.
- [30] Bocci V, Zanardi I, Travagli V. Oxygen/ozone as a medical gas mixture. A critical evaluation of the various methods clarifies positive and negative aspects. *Med Gas Res* 2011;1:6. <http://dx.doi.org/10.1186/2045-9912-1-6>.
- [31] Mendiratta S, Qu ZC, May JM. Enzyme-dependent ascorbate recycling in human erythrocytes: role of thioredoxin reductase. *Free Radic Biol Med* 1998;25:221–8.
- [32] Antunes F, Cadenas E. Estimation of H<sub>2</sub>O<sub>2</sub> gradients across biomembranes. *FEBS Lett* 2006;475:121–6.
- [33] Stone JR, Yang S. Hydrogen peroxide: a signaling messenger. *Antioxid Redox Signal* 2006;8:243–70.
- [34] Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. *Annu Rev Immunol* 1994;12:141–79.
- [35] Bocci V, Valacchi G, Corradeschi F, Fanetti G. Studies on the biological effects of ozone: 8. Effects on the total antioxidant status and on interleukin-8 production. *Mediators Inflamm* 1998;7:313–7.
- [36] Larini A, Bocci V. Effects of ozone on isolated peripheral blood mononuclear cells. *Toxicol In Vitro* 2005;19:55–61.
- [37] Valacchi G, Bocci V. Studies on the biological effects of ozone: 10. Release of factors from ozonated human platelets. *Mediators Inflamm* 1999;8:205–9.
- [38] Awasthi YC, Ansari GA, Awasthi S. Regulation of 4-hydroxynonenal mediated signaling by glutathione S-transferases. *Methods Enzymol* 2005;401:379–407.
- [39] Alary J, Guéraud F, Cravedi JP. Fate of 4-hydroxynonenal in vivo: disposition and metabolic pathways. *Mol Aspects Med* 2003;24:177–87.
- [40] Kirkby NS, Lundberg MH, Harrington LS, Leadbeater PD, Milne GL, Potter CM, et al. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. *Proc Natl Acad Sci U S A* 2012;109:17597–602.
- [41] Calabrese EJ. Hormesis is central to toxicology, pharmacology and risk assessment. *Hum Exp Toxicol* 2010;29:249–61.
- [42] Bocci V, Zanardi I, Travagli V. Ozone acting on human blood yields a hormetic dose-response relationship. *J Transl Med* 2011;9:66. <http://dx.doi.org/10.1186/1479-5876-9-66>.
- [43] Bocci V, Zanardi I, Michaeli V, Travagli V. Mechanisms of action and chemical-biological interactions between ozone and body compartments: a critical appraisal of the different administration routes. *Curr Drug Ther* 2009;4:159–73.
- [44] Nabuurs-Franssen MH, Slegers R, Huijberts MS, Wijnen W, Sanders AP, Walenkamp G, et al. Total contact casting of the diabetic foot in daily practice: a prospective follow-up study. *Diab Care* 2005;28:243–7.
- [45] Prompers L, Huijberts M, Apelqvist J, Jude E, Piaggese A, Bakker K, et al. Delivery of care to diabetic patients with foot ulcers in daily practice: results of the Eurodiale Study, a prospective cohort study. *Diab Med* 2008;25:700–7.
- [46] Travagli V, Zanardi I, Bocci V. Topical applications of ozone and ozonated oils as anti-infective agents: an insight into the patent claims. *Recent Pat Antiinfect Drug Discov* 2009;4:130–42.
- [47] Wainstein J, Feldbrin Z, Boaz M, Harman-Boehm I. Efficacy of ozone-oxygen therapy for the treatment of diabetic foot ulcers. *Diab Technol Ther* 2011;13:1255–60.
- [48] Valacchi G, Zanardi I, Sticozzi C, Bocci V, Travagli V. Emerging topics in cutaneous wound repair. *Ann N Y Acad Sci* 2012;1259:136–44.
- [49] Ajamieh H, Merino N, Candelario-Jalil E, Menéndez S, Martínez-Sánchez G, Re L, et al. Similar protective effect of ischaemic and ozone oxidative preconditionings in liver ischaemia/reperfusion injury. *Pharmacol Res* 2002;45:333–9.
- [50] Foglieni C, Fulgenzi A, Belloni D, Sciorati C, Ferrero E, Ferrero ME. Ozonated autohemotherapy: protection of kidneys from ischemia in rats subjected to unilateral nephrectomy. *BMC Nephrol* 2011;12:61. <http://dx.doi.org/10.1186/1471-2369-12-61>.
- [51] El-Sawalhi MM, Darwish HA, Mausouf MN, Shaheen AA. Modulation of age-related changes in oxidative stress markers and energy status in the rat heart and hippocampus: a significant role for ozone therapy. *Cell Biochem Funct* 2012. <http://dx.doi.org/10.1002/cbf.2930>.
- [52] Xu J, Kulkarni SR, Donepudi AC, More VR, Slitt AL. Enhanced Nrf2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice. *Diabetes* 2012;61:3208–18. <http://dx.doi.org/10.2337/db11-1716>.
- [53] Xue P, Hou Y, Chen Y, Yang B, Fu J, Zheng H, et al. Adipose deficiency of Nrf2 in ob/ob mice results in severe metabolic syndrome. *Diabetes* 2013 [in press].